Genetic variants of TREM2, a protein expressed selectively by microglia in the brain, are associated with Alzheimer's disease (AD). Starting from an unbiased protein microarray screen, we identified a set of lipoprotein particles (including LDL) and apolipoproteins (including CLU/APOJ and APOE) as ligands of TREM2. Binding of these ligands by TREM2 was abolished or reduced by disease-associated mutations. Overexpression of wild-type TREM2 was sufficient to enhance uptake of LDL, CLU, and APOE in heterologous cells, whereas TREM2 disease variants were impaired in this activity. Trem2 knockout microglia showed reduced internalization of LDL and CLU. b-amyloid (Ab) binds to lipoproteins and this complex is efficiently taken up by microglia in a TREM2-dependent fashion. Uptake of Ab-lipoprotein complexes was reduced in macrophages from human subjects carrying a TREM2 AD variant. These data link three genetic risk factors for AD and reveal a possible mechanism by which mutant TREM2 increases risk of AD.
In Brief
Yeh et al. show that TREM2 is a receptor for lipoproteins, including APOE and CLU, and thereby mediates uptake of lipoprotein-Ab complexes by microglia. The study links together three genetic risk factors of Alzheimer's disease and offers new insight into the mechanisms of Ab clearance.
INTRODUCTION
Expected to affect 40 million worldwide by 2020, Alzheimer's disease (AD) is the most prevalent cause of dementia with no approved disease-modifying treatment (Anders Wimo, 2010) . It is widely believed that the accumulation of b-amyloid (Ab) peptides, which can deposit in amyloid plaques and form toxic oligomers, plays a key role in AD pathogenesis (Hardy and Selkoe, 2002) . In familial forms of AD, mutations in amyloid precursor protein (APP) or APP-processing enzymes result in a relative increase of aggregation-prone Ab species, leading to early-onset forms of AD (De Strooper et al., 2012; Haass et al., 2012; Kandalepas and Vassar, 2014) . In late-onset AD (LOAD), it is thought that impairment of Ab clearance is a key factor behind disease progression (Holtzman and Zlokovic, 2007; Mawuenyega et al., 2010; Wildsmith et al., 2013) .
As LOAD accounts for the vast majority of AD cases, large efforts have been made to understand the underlying genetic risk factors in the disease (Karch and Goate, 2015; Rosenthal and Kamboh, 2014) . In LOAD, apolipoprotein E (APOE) is the biggest risk factor. In humans there are three isoforms of APOE (APOE2-4), with APOE2 being a protective allele and APOE4 a risk allele for AD (Corder et al., 1993; Holtzman et al., 2012; Kanekiyo et al., 2014; Saunders et al., 1993; Strittmatter et al., 1993a) . In addition, both protective and detrimental SNPs in clusterin (CLU; also known as apolipoprotein J [APOJ] ), are associated with AD (Harold et al., 2009; Lambert et al., 2009) . The AD risk allele of CLU is associated with reduced CLU expression levels while the protective allele is associated with increased expression (Allen et al., 2012; Ling et al., 2012) . Mouse knockout (KO) studies have shown that loss of either Apoe or Clu results in reduced amyloid plaque deposition, perhaps via a decrease in Ab seeding (Bales et al., 1997; DeMattos et al., 2004; Holtzman et al., 2012) . In addition, APOE influences the clearance and metabolism of Ab, possibly through competition for the same receptors or alternatively via APOE acting as a chaperone for Ab (Castellano et al., 2011; Holtzman et al., 2012; Kanekiyo et al., 2014) . However, the molecular mechanisms and cellular pathways by which APOE and CLU affect Ab clearance and influence the risk of AD remain poorly understood.
With the advent of genome sequencing, many rare genetic variants have been linked to AD (Del-Aguila et al., 2015; Jonsson et al., 2012; Karch and Goate, 2015; Tanzi, 2012) . Triggering receptor expressed on myeloid cells 2 (TREM2) is a recently discovered AD risk gene (Guerreiro et al., 2013c; Jonsson et al., 2013 ) that encodes a single-transmembrane (STM) protein expressed by monocytic myeloid cells. In the brain, TREM2 is selectively expressed in microglia, the innate immune cells of the CNS (Klesney-Tait et al., 2006; Zhang et al., 2014) . The TREM2 R47H allele, which has an odds ratio of $2.9-4.5 (Guerreiro et al., 2013c; Jonsson et al., 2013) , appears to decrease the age of onset of AD by $3 years (Jonsson et al., 2013) . Additional TREM2 variants, R62H and D87N, have been linked to AD (Guerreiro et al., 2013c; Jin et al., 2014) . The R47H mutation has been suggested to be a loss-of-function mutation , while the R62H and D87N variants have not been functionally characterized. These data imply that microglia play an important role in the pathogenesis of AD.
Besides AD, loss-of-function mutants of TREM2 (Q33X, Y38C, and T66M) in homozygous state cause Nasu-Hakola disease (NHD), a severe recessive disease characterized by bone cysts as well as neurodegeneration and white matter loss by the fourth decade of life. These pathologies are thought to occur due to a defect in osteoclasts in bone remodeling and dysfunctional microglia in the brain (Klesney-Tait et al., 2006; Kondo et al., 2002; Paloneva et al., 2002) .
The physiological function of TREM2 in the brain is poorly understood. Based on earlier experiments, TREM2 has been implicated in anti-inflammatory signaling in monocytes and microglia by inhibiting Toll-like receptor signaling (Klesney-Tait et al., 2006; Turnbull et al., 2006) and promoting phagocytosis of apoptotic cell membranes (Hsieh et al., 2009; Kawabori et al., 2015; Klesney-Tait et al., 2006; Takahashi et al., 2005) . Deficiency of Trem2 in the 5xFAD mouse model of AD increased amyloid accumulation and exacerbated neuronal loss , while overexpression of TREM2 in the APP/PS1 AD mouse model ameliorated neuropathology . However, the mechanism behind the protective function of TREM2 remains unclear.
We hypothesized that TREM2 has extracellular ligands whose binding is affected by the AD-and NHD-associated mutations, most of which are amino acid (aa) substitutions in the extracellular Ig-like V-type domain of TREM2. The extracellular region of TREM2 has been proposed to bind a variety of molecules, including phospholipids, apolipoproteins, PlexinA1, and Hsp60 (Atagi et al., 2015; Bailey et al., 2015; Stefano et al., 2009; Takegahara et al., 2006; Wang et al., 2015) ; but, how these ligands link TREM2 to AD is unclear. We performed a large unbiased screen of an extracellular recombinant protein library representing 1,559 extracellular proteins, and we identified a set of lipoprotein particles and apolipoproteins as ligands of TREM2. Importantly, the TREM2 ligands include APOE and CLU, which are themselves risk genes for AD, and their binding is impaired by TREM2 mutations that confer AD risk. Moreover, we provide evidence that, through its interaction with lipoproteins, TREM2 can facilitate Ab uptake by microglia and human macrophages.
RESULTS

Unbiased Identification of TREM2 Ligands by Protein Microarray Screen
We previously have developed and characterized a human protein microarray (PM) platform for identifying extracellular proteinprotein interactions (Ramani et al., 2012; Tom et al., 2013) . These arrays consist of purified extracellular domains of STM proteins and secreted ligands immobilized on epoxy-derivatized glass slides, and they have been used to identify several novel receptor-ligand interactions (Haddick et al., 2014; Jaworski et al., 2015; Lobito et al., 2011) . The PM library represents 1,559 genes, encoding $50% of the predicted human STM and secreted proteins (Table S1) .
To identify potential ligands for TREM2 using this platform, we purified the extracellular domain of human TREM2 (hTREM2, aa 19-174) fused at the C terminus to the Fc portion of human IgG1 (TREM2-Fc). The screen with TREM2-Fc identified the following seven hits that showed clear separation from the background: apolipoprotein A1 (APOA1), low-density lipoprotein (LDL), malondialdehyde-modified LDL (MDA-LDL), neuritin 1-like (NRN1L), secretoglobin 2A2 (SCGB2A2), growth hormone 1 (GH1), and unc-5 homolog B (UNC5B) ( Figures 1A and 1C-1G) . To confirm the specificity of these hits, we repeated the full PM screen with the extracellular domain of TREM1, another TREM family member that also might be linked to AD (Replogle et al., 2015) but that shares <20% aa identity in the extracellular domain. The TREM1-Fc screen did not yield any strong hits or show significant binding to any of the TREM2 candidate ligands ( Figures 1B, 1H , and 1I).
Using bio-layer interferometry (BLI) as an independent orthogonal method to measure protein-protein interaction, we confirmed that APOA1, LDL, as well as oxidized LDL (oxLDL) and MDA-LDL, showed robust binding to TREM2-Fc (Figures 2A  and 2B ; Figures S1A and S1C), but not to control Fc-fusion proteins (Figures S1B, S2A, and S2B). Other hits from the TREM2-Fc microarray screen failed to replicate in BLI assays, resulting in either no binding (NRN1L) or background binding (SCGB2A2, GH1, and UNC5B) (data not shown).
hTREM2 Binds to Lipoprotein Particles and Apolipoproteins APOA, APOB, CLU, and APOE We investigated whether hTREM2 binds to other human lipoprotein particles and apolipoproteins. We found that, in addition to LDL, TREM2-Fc bound to very-low-density lipoprotein (VLDL), high-density lipoprotein (HDL), and lipoprotein [Lp(a)] (Figure 2A ), whereas TREM1-Fc did not ( Figure S2A ). As apolipoproteins are found physiologically in a lipidated state in the form of lipoproteins, we used dimyristoyl-phosphocholine (DMPC) to artificially lipidate these proteins to test their interactions via BLI. We found that TREM2-Fc, but not TREM1-Fc, bound to lipidated APOA1 and lipidated APOA2, which are major components of HDL particles ( Figure 2B ; Figure S2B ) (Calero et al., 1999; Kanekiyo et al., 2014) . We also assayed for binding to APOB, a major apolipoprotein component of LDL and VLDL particles (Walldius and Jungner, 2004) . By BLI measurements, purified APOB bound robustly to TREM2-Fc, but not TREM1-Fc ( Figure 2B ; Figure S2B) . Curiously, our lipidation protocol for apolipoproteins abolished APOB binding to TREM2-Fc. It is possible, because of the much larger size of APOB compared to the other apolipoproteins tested here (APOB: 515 kDa versus APOA1/2: 28 kDa), that APOB co-purifies with its required lipids (i.e., purified APOB is already associated with lipids), while our DMPC lipidation protocol results in a loss of activity.
HDL-like particles containing APOE and CLU are present in the brain and are mainly produced by glia (DeMattos et al., 2001) . Both APOE and CLU are genetically linked to AD, so we tested whether TREM2 interacted with these two apolipoproteins. Interestingly, TREM2-Fc interacted with both lipidated APOE and lipidated CLU, but not with lipid particles made from DMPC alone (Figures 2C and 2D ; Figures S1D and S1E ). TREM1-Fc did not bind to either CLU or APOE, regardless of their lipidation state ( Figures S2C and S2D) . APOA2, CLU, and APOE were represented on the microarray and did not appear as positive hits in the TREM2-Fc screen, likely because these apolipoproteins were purified without lipidation.
TREM2 Disease Mutations Reduce Binding to LDL, CLU, and APOE What are the effects of the AD risk variants of hTREM2 on apolipoprotein and lipoprotein binding? We focused on three AD-associated variants (R47H, R62H, and D87N), two NHD mutations (Y38C and T66M), and a predicted null mutant K48M, which was designed by modeling hTREM2 with the TREM1 crystal structure (PDB: 1SMO) ( Figure 3A ) (Kelker et al., 2004) . Binding was measured by BLI using the same amount of each of the TREM2-Fc variants (in the form of Fc fusions). Consistent with complete loss of function inferred from human genetics, the NHD mutants Y38C and T66M showed no appreciable binding to LDL, similar to K48M ( Figures 3B and 3C ). Of the three AD-associated variants, R47H exhibited the largest relative reduction (55%) in binding to LDL compared to wild-type (WT). D87N showed a 47% decrease in LDL binding, while the R62H variant was more modestly impaired (17% decrease) ( Figure 3C ).
The relative binding of lipidated CLU to TREM2-Fc variants followed a similar trend as LDL ( Figure 3D ). The NHD mutants of hTREM2 showed no detectable binding to lipidated CLU. R47H and D87N both exhibited a 40% reduction in binding to CLU as compared to WT TREM2-Fc; R62H was slightly, but nonetheless significantly, impaired (12% reduction) ( Figure 3E ). We also tested APOE binding to the variants of hTREM2 and found the binding profiles were closely matched to those of CLU ( Figures 3F and 3G ). The AD mutants R47H (51% reduction), D87N (52% reduction), and R62H (22% reduction) all exhibited partial loss of function, while the NHD mutants had no detectable binding to lipidated APOE, similar to K48M.
Expression of TREM2 Is Sufficient to Induce Uptake of AcLDL, CLU, and APOE in Heterologous Cells
To investigate the functional significance of TREM2 binding to apolipoproteins and lipoprotein particles, we created stable HEK293 cell lines expressing WT and mutant forms of hTREM2 . BSA-Cy3 is spotted in pairs between each individual library protein, which is also spotted in duplicate, to help localize sample positions on the microarray. White boxes denote areas around three prominent hits for TREM2-Fc in library 1 of the microarray. (C-E) Enlargements of the microarray are shown for the area around each hit and the identity of each protein is overlaid over the spots. The interactions between TREM2-Fc and (C) APOA1, (D) MDA-LDL, and (E) LDL are clearly visible as red dots. The data analysis and scoring system for the microarray are described in the Experimental Procedures. (F-I) Each scatterplot represents two replicate microarray datasets (arrays 1 and 2), with scores for each protein in the library represented as a dot. An empirically set cutoff of 5 (inner square) was used to define hits. (F) LDL, MDA-LDL, APOA1, and GH were identified as hits for TREM2-Fc in library 1, and (G) SCGB2A2, UNC5B, and NRN1L were identified as hits for TREM2-Fc in library 2. (H and I) The PM library also was screened for binding to TREM1-Fc, which showed no positive hits.
under the control of a doxycycline (Dox)-inducible promoter (hTREM2-Dox cell lines; Figure S3A ). We first compared LDL uptake between induced and uninduced WT hTREM2-Dox cells, but we did not see an appreciable change in uptake with hTREM2 expression ( Figure S3B ). We hypothesized that high basal internalization of LDL, due to expression of LDL receptor (LDLR) in HEK293 cells (Poirier et al., 2009) , as well as an inability to dose higher concentrations of LDL, possibly occluded the effect of hTREM2 expression.
To circumvent endogenous LDLR expression, we tested acetylated LDL (AcLDL), which does not bind to LDLRs (Weisgraber et al., 1978) but binds to hTREM2 ( Figure S1A ). Following Dox induction, cells expressing WT hTREM2 showed a marked increase in uptake of DiI-labeled AcLDL when compared to uninduced cells ( Figure 4A ). The extracellular fluorescence signal was quenched using trypan blue to confirm that the DiI-AcLDL signal was internalized within the cells. A time course revealed an $2.4-fold increase in the rate of internalization of DiI-labeled AcLDL in induced hTREM2-expressing cells versus uninduced cells ( Figure 4B ). Dox-induced WT hTREM2-Dox cells also were able to take up lipidated CLU and lipidated APOE (as measured by western blotting of cell lysates), whereas uninduced cells failed to do so to a detectable degree (Figures 4C-4E ). These data demonstrate that heterologous expression of hTREM2 is sufficient to mediate cellular uptake of LDL, CLU, and APOE.
We also investigated whether hTREM2-Dox cells exhibited differential uptake of APOE isoforms, and we found that lipidated recombinant APOE2, APOE3, or APOE4 was taken up with similar efficiency (Figures S3C and S3D ). This finding is consistent with reports that show no difference in binding of TREM2 to APOE2, 3, and 4 (Atagi et al., 2015; Bailey et al., 2015) .
Next we tested the effect of AD-or NHD-associated mutations on the ability of TREM2 to mediate uptake of lipoprotein ligands. We generated cell lines that expressed each of the five hTREM2 mutant proteins at similar levels to each other and to WT after Dox induction ( Figure S3A ). Cells expressing the NHD mutants Y38C (19% ± 7% of WT) and T66M (9% ± 5% of WT) exhibited severely reduced uptake of AcLDL compared with WT hTREM2 (Figures 4F and 4G ). Among the AD-associated mutants, R47H was markedly impaired in AcLDL uptake (8% ± 3% of WT), whereas D87N (58% ± 9% of WT) and R62H (53% ± 5% of WT) showed a moderate loss of AcLDL uptake (Figures 4F and 4G) .
When we tested uptake of lipidated CLU by induced hTREM2-Dox cells ( Figures 4H and 4I ), we found that mutants Y38C (18% ± 5% of WT) and T66M (12% ± 3% of WT) were greatly impaired in uptake of CLU. Mutants R47H (48% ± 8% of WT) and D87N (70% ± 11% of WT) showed a moderate reduction of CLU uptake, although the D87N result did not reach statistical significance. In contrast to its impaired uptake of AcLDL, the R62H mutant was similar to WT in mediating uptake of artificially lipidated CLU.
Taken together, our data demonstrate that disease-linked mutations in the extracellular Ig domain of TREM2 not only affect (D) TREM2-Fc also bound to lipidated APOE, but not unlipidated APOE. Protein concentrations were 10 mg/ml and lipid concentrations were 10 mg/ml for the BLI experiments, except where noted. Black arrows indicate when probe was switched into dissociation buffer (PBS).
binding of certain apolipoproteins and lipoprotein particles but also have functional consequences on the uptake of these ligands into cells, with the NHD mutations in general showing a more severe impairment than the AD-associated mutations.
TREM2 Deficiency in Microglia Reduces CLU and LDL Uptake
To investigate the role of endogenous TREM2 in lipoprotein binding and processing, we turned to microglia, the cell type in the brain that expresses TREM2. We first confirmed using BLI that mouse TREM2 (mTREM2) could bind human LDL particles (Figure S4) . We then tested whether LDL uptake was affected by the loss of TREM2. Primary microglia purified and cultured from Trem2 KO mice showed an $40% reduction in uptake of DiIlabeled LDL compared with WT microglia ( Figure 5A , quantified in Figure 5B ). Analysis of the time course of DiI-LDL uptake by flow cytometry corroborated a slower rate of LDL uptake by Trem2 KO microglia ( Figure 5C ). These findings confirm that TREM2 is required, at least in part, for the ability of microglia to take up LDL. Microglia also express known LDLRs, such as Error bars represent SEM (**p < 0.01 and ***p < 0.001). Black arrows indicate when probe was switched into dissociation buffer (PBS). All protein concentrations were 30 mg/ml and lipid concentrations were 10 mg/ml for lipidated material.
Lrp1 ( Figure S5 ) , and such receptors might be responsible for the residual uptake of LDL into Trem2 KO microglia.
To evaluate whether TREM2 also plays a role in CLU or APOE uptake, we assayed microglia uptake of CLU and APOE from mouse astrocyte-conditioned medium (ACM). Trem2 KO microglia showed a significant decrease in CLU uptake as compared to WT microglia ( Figures 5D and 5E) , similar to what we observed with LDL. We were unable to detect any uptake of APOE from ACM even in WT microglia ( Figures 5F and 5G) , possibly due to the already high levels of endogenous APOE in microglia (see Figure 5F, left lanes, no ACM treatment). Thus, we were unable to evaluate whether APOE uptake was affected by the loss of TREM2 in cultured microglia.
Trem2 KO Microglia Are Impaired in the Uptake of Ab Complexed with Lipoproteins Ab has been reported to bind to apolipoproteins such as APOE and CLU Strittmatter et al., 1993b) , and neuritic plaques contain CLU and APOE in addition to Ab Namba et al., 1991) . Clearance of Ab plaques or soluble Ab by microglia is thought to be a major mechanism for preventing the accumulation of Ab in the aging brain. We therefore explored whether lipoprotein ligands of TREM2 such as CLU and LDL-by binding both Ab and TREM2-can act as a carrier for Ab to facilitate Ab uptake by microglia. Indeed, when we mixed fluorescein isothiocyanate (FITC)-labeled Ab 1-42 (FITC-Ab) aggregates (see the Experimental Procedures) together with DiI-labeled LDL or lipidated CLU, we found that a substantial proportion of the Ab aggregates floated with the lipoprotein particles upon step-gradient-density ultracentrifugation, implying binding of Ab to LDL or CLU lipoproteins ( Figure 6A ). Using this step-gradient-density centrifugation, we purified the Ab-lipoprotein complexes based on their lower density, while free Ab aggregates fractionated at the bottom of the tube ( Figure 6A ).
When incubated with gradient-purified Ab-LDL complex or free Ab (at the same total concentration of Ab), WT microglia were markedly more efficient at taking up Ab in the form of Ab-LDL complex than as free Ab ( Figure 6B ) (FITC-Ab uptake by microglia quantified by flow cytometry [ Figure S6] ). The uptake of Ab-LDL complex was substantially impaired in Trem2 KO microglia when compared with WT microglia ( Figure 6B; Figure S7A ). Of note, the uptake of Ab-LDL complex by microglia from Trem2 heterozygous (HET) mice was intermediate between that of WT and homozygous KO microglia ( Figure 6B; Figure S7A) . Thus, normal uptake of Ab-LDL by microglia not only requires TREM2 but also depends on the gene dosage of Trem2. Consistent with our hypothesis that TREM2 mediates uptake of Ab through an Ab-LDL complex, we observed that DiI-LDL uptake (when we added FITC-Ab-DiI-LDL complex to (G) Quantification of DiI-AcLDL uptake by hTREM2 variants (normalized to WT hTREM2) showed a significant reduction of DiI-AcLDL internalization for all mutant forms of hTREM2 (n = 51, one-way ANOVA with Tukey's multiple comparison test). (H) Dox-induced cell lines expressing WT and mutant hTREM2 were incubated with lipidated CLU for 2 hr, and cell lysates were analyzed by western blot for CLU uptake (protein concentrations: 3 mg/ml; lipid concentrations: 10 mg/ml). (I) Quantification of CLU uptake (normalized to WT hTREM2) showed significant reduction in hTREM2-Dox lines expressing Y38C, T66M, and R47H versus WT (n = 3, one-way ANOVA with Tukey's multiple comparison test). Error bars represent SEM (**p < 0.01 and ***p < 0.001). All concentrations refer to protein concentrations. microglia) was reduced robustly in Trem2 KO microglia compared with WT microglia and to an intermediate degree in Trem2 HET microglia ( Figure 6C ; Figure S7A ).
We performed similar experiments to test whether lipidated CLU, a ligand of TREM2 present within the brain, could serve as a carrier for Ab uptake. Indeed, WT microglia were more efficient in uptake of Ab when incubated with the gradient-purified Ab-CLU complex than with free Ab at the same Ab concentration ( Figure 6D) . Remarkably, the uptake of Ab-CLU complex by microglia was again dependent on Trem2 gene dosage: uptake of Ab-CLU was strongly reduced in Trem2 KO microglia compared to WT microglia, whereas Trem2 HET microglia were impaired to an intermediate degree ( Figure 6D ; Figure S7B ). Although the difference of Ab-CLU uptake between Trem2 WT and HET microglia did not reach statistical significance, there was a trend similar to what we observed with Ab-LDL uptake. Note that the effect size was slightly smaller than for the Ab-LDL complex; we hypothesize this could be due to the use of a synthetically lipidated CLU molecule as opposed to a natural lipid particle, such as LDL. Taken together, our findings indicate that, by directly binding to lipoproteins such as CLU, TREM2 expressed on microglia could play a role in the uptake and, thus, clearance of extracellular Ab aggregates that are associated with lipoproteins.
We measured the rate of degradation of Ab following uptake by WT versus Trem2 KO microglia. When fed with free Ab, there was no difference in the time course of degradation of internalized Ab between these two genotypes ( Figure 6E ). After uptake of Ab-LDL complexes, however, Ab degradation was faster in WT microglia than in Trem2 KO microglia ( Figure 6F ). These data suggest that the uptake of Ab-LDL complexes mediated by TREM2 allows faster degradation of Ab than uptake by TREM2-independent mechanisms. (E and G) Quantification of time course of (E) CLU and (G) APOE uptake, normalized to t = 0 (n = 6, two-way ANOVA). Error bars represent SEM (*p < 0.05 and ***p < 0.001).
TREM2 R62H Human Macrophages Take Up Less Ab-LDL Complex
To extend our findings to humans, we screened $1,500 donors in the Genentech Genotype and Phenotype Registry within our Employee Blood Donation program and identified six subjects that had one allele of R62H TREM2 (Table S2) . We derived monocyte-derived macrophages (MDMs) from these R62H carriers, and we tested their ability to take up Ab compared to MDMs from age-, gender-, and ethnicity-matched controls ( Figures  7A and 7B) . Like mouse microglia, human MDMs from all subjects were more efficient in uptake of Ab-LDL complexes as compared to free Ab of the same concentration. Notably, MDMs from R62H carriers showed a modest but highly significant reduction in uptake of Ab-LDL complexes compared to matched controls ( Figure 7B ). These results suggest that human MDMs heterozygous for the R62H AD mutation have a defect in Ab-lipoprotein handling, further supporting a role for TREM2 in the clearance of lipoprotein-associated Ab aggregates.
DISCUSSION
Human genetic data increasingly highlight innate immune cells such as microglia playing a role in determining the risk of LOAD. A recent example is TREM2, a risk gene expressed specifically on myeloid cells, including microglia (Guerreiro et al., 2013c; Jonsson et al., 2013) . TREM2 has been reported to bind to phospholipids, but the significance of these interactions in AD biology is not well understood (Poliani et al., 2015; Wang (B) FITC-Ab-DiI-LDL complex isolated as shown in (A) or free FITC-Ab (both at 0.1 mM concentration of Ab) was added to microglia for 15 min, 30 min, 1 hr, 2 hr, 3 hr, or 4 hr. The uptake of FITC-Ab or DiI-LDL was measured by flow cytometry based on the mean fluorescence intensity of FITC or DiI, respectively. The association with LDL greatly boosted the uptake of Ab versus free Ab (measured by FITC fluorescence intensity). Trem2 KO microglia were strongly impaired and Trem2 HET microglia were moderately impaired in uptake of the complex. (C) DiI-LDL uptake, from FITC-Ab-DiI-LDL complexes, was also TREM2 dependent, with a similar trend to Ab (n = 8 for WT and Trem2 KO; n = 5 for Trem2 HET; two-way ANOVA). (D) FITC-Ab-APOJ complex was isolated by step gradient as in (A). Similar to LDL, Ab-CLU complex was taken up more efficiently by microglia compared to free Ab (both at 0.1 mM concentration of Ab). Uptake of Ab-CLU complex was TREM2 dependent (n = 5, two-way ANOVA). All points were normalized to WT microglia uptake of Ab complexes at 4 hr. (E and F) Time course of degradation of Ab after uptake by WT versus Trem2 KO microglia. Microglia were incubated with either (E) free Ab or (F) Ab-LDL complexes for 2 hr. After washing, the amount of Ab remaining at each time point was measured by Meso Scale Diagnostics Ab immunoassay and normalized to t = 0 hr (immediately after Ab-containing media were removed and cells were washed) (n = 4, two-way ANOVA). Error bars represent SEM (***p < 0.001).
et al., 2015). Here, starting from an unbiased screening of $1,500 STM and secreted proteins, we found that TREM2 interacts selectively and directly with a set of apolipoproteins and lipoprotein particles, including two known risk factors for AD, CLU, and APOE (Harold et al., 2009; Lambert et al., 2009; Saunders et al., 1993; Strittmatter et al., 1993a) . Independently, a recent study identified APOE, APOA1, and APOA2 as putative TREM2 ligands by TREM2-Fc fusion pulldown from cynomolgus cerebrospinal fluid (CSF) and serum (Bailey et al., 2015) . Using a candidate approach, Atagi et al. (2015) showed that TREM2 can bind to APOE, APOA1, and APOB in dot blot binding assays. Our study confirms and extends TREM2 interactions with apolipoproteins using high-throughput PM screening, backed by quantitative BLI measurements. Of note, we find that hTREM2 binds to CLU as well as APOE and that hTREM2 binding is greatly enhanced by lipidation of these apolipoproteins, which reflects their natural state in vivo (Calero et al., 1999 DeMattos et al., 2001; Mahley and Rall, 2000) . Consistent with this, we found that hTREM2 interacts with multiple lipoprotein particles, including LDL. It is possible that TREM2 binding to CLU was not detected previously due to the lack of lipidation (Bailey et al., 2015) .
We performed a comprehensive quantitative analysis of the effects of hTREM2 mutations on lipoprotein binding and uptake into cells. All AD and NHD mutations impaired the ability of hTREM2 to bind to LDL, CLU, and APOE. Interestingly, there was a correlation between a complete loss of apo/lipoprotein binding and the NHD mutants (Y38C and T66M) versus a partial loss of binding and the AD-associated variants (R47H, R62H, and D87N). The null-binding phenotype-and the homozygous nature of the mutation-could explain the severity and early onset of NHD relative to AD. Among the AD mutants, there is a correlation between LDL and CLU binding (R47H and D87N more severely impaired than R62H) and the degree of risk conferred for AD (R47H has an odds ratio of $3 and R62H an odds ratio of $1.5) . The D87N variant is too rare for reliable estimation of its odds ratio. Importantly, the biochemical binding data correlate with cellular uptake data: in general, the NHD mutants of hTREM2 were more severely impaired than the AD mutants in their ability to take up LDL or lipidated CLU into heterologous cells. In addition to disruption of lipoprotein binding (which was directly tested in our study), TREM2 disease-associated mutations may also differentially affect cell surface expression of TREM2 protein (Kleinberger et al., 2014) .
We sought to determine how the interactions between TREM2 and lipoproteins might be functionally relevant to the pathogenesis of AD, a disease characterized by abnormal Ab accumulation in the brain. Consistent with the direct binding experiments and heterologous cell uptake data, TREM2-deficient microglia were defective in uptake of apo/lipoproteins such as LDL and CLU. As the major phagocytic cell in the brain, microglia are proposed to function in the clearance of Ab (Bradshaw et al., 2013; El Khoury et al., 2007; Griciuc et al., 2013; Wang et al., 2015; Wyss-Coray et al., 2002) . It is notable that oligomeric and aggregated forms of Ab have been found to interact with recombinant APOE as well as cell-, CSF-, and plasma-derived APOE (LaDu et al., 1994; Strittmatter et al., 1993b; Tokuda et al., 2000; Wisniewski et al., 1993) . We show here that Ab aggregates also bind to lipidated CLU. Additionally, both APOE and CLU are found in neuritic plaques Namba et al., 1991) . Therefore, by binding directly to lipoproteins and internalizing them, TREM2 can function to scavenge toxic extracellular molecules like Ab that associate with lipoprotein particles (estimates range from 5% to 100% of Ab being associated with lipoproteins in human CSF) (LaDu et al., 2012; Verghese et al., 2013) .
In support of this idea, we found that microglia are much more efficient in the uptake of Ab aggregates when complexed with LDL or lipidated CLU than Ab aggregates in the free state. Remarkably, the uptake of Ab-LDL or Ab-CLU complexes by microglia depended on Trem2 in a gene dose-dependent manner, such that even loss of a single copy of the Trem2 gene resulted in an intermediate impairment of Ab-lipoprotein uptake. This observation is significant because AD risk is typically conferred by TREM2 mutations in the heterozygous state (Guerreiro et al., 2013c; Jonsson et al., 2013) . Our data with MDMs from human subjects support the thesis that a heterozygous mutation in TREM2 (in this case R62H) can significantly impair microglial uptake of Ab-lipoprotein complexes.
In addition to binding soluble Ab aggregates (this study; LaDu et al., 1994; Strittmatter et al., 1993a; Tokuda et al., 2000; Wisniewski et al., 1993) , the association of APOE and CLU with neuritic plaques raises the possibility that microglia can attack amyloid through TREM2 binding to apolipoproteins within the plaque (Liao et al., 2014) . Thus, APOE and CLU could facilitate microglial Ab uptake and clearance by binding to soluble Ab aggregates or by associating with Ab aggregates deposited in amyloid plaques. By either mechanism, impairment or loss of function of TREM2 would be expected to favor accumulation of Ab in the brain. The functional significance of TREM2 binding to lipoproteins and Ab-lipoprotein complexes remains to be studied in vivo. Previous studies in the 5xFAD mouse model of AD found that loss of TREM2 exacerbated amyloid pathology , consistent with our hypothesis; however, see Jay et al. (2015) for a conflicting conclusion.
Mild impairment of Ab uptake and clearance by microglia as a result of reduced ability to bind apolipoproteins may explain why those with heterozygous TREM2 mutations are predisposed to amyloid accumulation during aging and hence LOAD. How do TREM2 mutations cause NHD? We speculate that, in addition to the binding of extracellular Ab, APOE and CLU lipoproteins in the brain also bind to other extracellular aggregates and cellular debris and thereby help TREM2-bearing microglia to clean up apoptotic cells and other pathogenic protein aggregates (Wyss-Coray, 2006) . Indeed, APOE has been reported to bind to apoptotic N2a cells and enhance the engulfment of apoptotic N2a cell membranes by microglia (Atagi et al., 2015) . Impaired clearance of cellular and extracellular debris might explain why severe TREM2 deficiency, such as occurs with homozygous loss-of-function mutations, causes NHD and frontotemporal dementia (Giraldo et al., 2013; Guerreiro et al., 2013a Guerreiro et al., , 2013b Kondo et al., 2002; Paloneva et al., 2002) .
The ability of TREM2 to bind two known AD risk factors (APOE and CLU) and its strong influence on Ab uptake, via lipoprotein association with Ab aggregates, could explain the large genetic influence of TREM2 mutation on AD risk. Previous studies have implicated other lipoprotein receptors, LDLR and LRP1, in Ab metabolism, with deficiency of LDLR and a reduction in LRP1 expression increasing amyloid pathology (Basak et al., 2012; Cao et al., 2006; Van Uden et al., 2002) and overexpression of LDLR leading to lower plaque load in AD mouse models (Kim et al., 2009) . The interactions between TREM2 and CLU/APOE biochemically link these three genetic risk factors and functionally connect innate immune cells and lipoproteins in AD.
EXPERIMENTAL PROCEDURES
See the Supplemental Experimental Procedures for experimental details relating to materials and animals, protein expression and purification, protein-binding assays, cell culture, and preparation of Ab aggregates and Ab-lipoprotein complexes.
PM Screen
Assembly of extracellular protein libraries, construction of PMs, automated processing of microarrays, and microarray analyses have been described in detail (Ramani et al., 2012; Tom et al., 2013) . Briefly, TREM2-Fc or another Fc-fusion protein was bound to Protein A-coated nanobeads (Miltenyi Biotec) along with Cy5-labeled IgG as a fluorescent probe. Beads were incubated with the microarrays for 45 min and washed with PBS with 0.1% Tween 20, dried, and scanned for Cy5 fluorescence on a GenePix 4000B scanner. Data were analyzed using GenePix Pro 6.0 software (Molecular Devices). The downstream data processing methodology and the scoring system are described in Tom et al. (2013) . The score represents the average intensity of the replicate spots for each protein on the microarray divided by the square root of the intensity difference, plus a stabilizing factor that is empirically set to a value of 2. This scoring mechanism penalizes for large differences between replicate spot intensities, which may not represent robust binding events.
LDL, CLU, and APOE Uptake Assays HEK293 hTREM2-Dox stable cell lines were grown in 96-well glass-bottom Matriplates (Brooks) and incubated with 25 mg/ml DiI-AcLDL for the indicated time before the cells were washed and incubated with CellTracker Green for 30 min at 37 C. Cells were washed and trypan blue was added to the cells to quench extracellular DiI signal. The samples were imaged using an InCell 2000 (GE Healthcare Life Sciences). Quantification of DiI signal, relative to cell area (marked by CellTracker Green), was performed using InCell Developer (GE Healthcare Life Sciences). For DiI-LDL experiments, 80,000 primary microglia cells were seeded in 96-well glass-bottom Matriplates (Brooks). DiI-LDL (25 mg/ml) was added to the microglia and incubated for 4 hr. Cells were washed and incubated with 5 mg/ml Hoechst for 5-10 min to mark nuclei. Cells were washed and trypan blue was added to cells to quench extracellular signal. Plates were imaged using an InCell 2000 (GE Healthcare Life Sciences). Quantification of the DiI fluorescence, relative to cell number (marked by Hoechst), was performed using InCell Developer (GE Healthcare Life Sciences).
For human CLU and APOE uptake, HEK293 hTREM2-Dox cells were grown in 48-well plates and induced with 1 mM Dox in 0% or 1% serum media overnight. Cells were incubated for 2 hr with 3 mg/ml lipidated APOE or CLU in the presence of 1% BSA. Cells were washed extensively with Hank's balanced salt solution (HBSS) before cell lysis and analysis via SDS-PAGE.
For CLU and APOE uptake by microglia, ACM was added to microglia cells in the presence of chloroquine (30 mM) to inhibit degradation. Cells were harvested at indicated times and lysates were used to perform SDS-PAGE analysis.
Ab Uptake and Degradation
Primary microglia or MDMs were serum starved overnight before the addition of Ab, Ab-LDL, or Ab-CLU. Following a period of time for Ab uptake, cells were dislodged using enzyme-free PBS-based cell dissociation buffer (Thermo Fisher Scientific). Cells were washed and resuspended in flow cytometry buffer (13 PBS, 0.5% BSA, and 0.05% sodium azide) and kept on ice. Sytox blue staining was used to identify live cells. Flow cytometry was done using LSRFortessa (BD Biosciences) and the mean FITC/DiI fluorescence intensity was analyzed.
For Ab degradation experiments, microglia cultures were incubated with free Ab aggregates (0.1 mM) or Ab-LDL complexes (0.01 mM Ab) for 2 hr, after which they were washed with media and placed back into fresh media. Cells were lysed at 0, 1, 3, 5, or 7 hr, and the amount of remaining Ab in the cell lysate was measured by Meso Scale Diagnostics immunoassays. 
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